180 related articles for article (PubMed ID: 35603979)
1. Survival, cost and added therapeutic benefit of drugs granted early access through the French temporary authorization for use program in solid tumors from 2009 to 2019.
Pham FY; Jacquet E; Taleb A; Monard A; Kerouani-Lafaye G; Turcry F; Brunel L; Grudé F; Yoldjian I; Sainte-Marie I; Boudali L; Blay JY; Albin N
Int J Cancer; 2022 Oct; 151(8):1345-1354. PubMed ID: 35603979
[TBL] [Abstract][Full Text] [Related]
2. Prices and clinical benefit of cancer drugs in the USA and Europe: a cost-benefit analysis.
Vokinger KN; Hwang TJ; Grischott T; Reichert S; Tibau A; Rosemann T; Kesselheim AS
Lancet Oncol; 2020 May; 21(5):664-670. PubMed ID: 32359489
[TBL] [Abstract][Full Text] [Related]
3. Examining the association between oncology drug clinical benefit and the time to public reimbursement.
Thomson S; Everest L; Witzke N; Jiao T; Delos Santos S; Nguyen V; Cheung MC; Chan KKW
Cancer Med; 2022 Jan; 11(2):380-391. PubMed ID: 34850587
[TBL] [Abstract][Full Text] [Related]
4. Clinical benefit and cost of breakthrough cancer drugs approved by the US Food and Drug Administration.
Molto C; Hwang TJ; Borrell M; Andres M; Gich I; Barnadas A; Amir E; Kesselheim AS; Tibau A
Cancer; 2020 Oct; 126(19):4390-4399. PubMed ID: 32697362
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of changes in the clinical benefits of oncology drugs over time following reimbursement using the ASCO-VF and the ESMO-MCBS.
Yoon NR; Na YJ; Lee JH; Song I; Lee EK; Park MH
J Cancer Res Clin Oncol; 2024 Mar; 150(3):113. PubMed ID: 38436796
[TBL] [Abstract][Full Text] [Related]
6. Clinical benefit of cancer drugs approved in Switzerland 2010-2019.
Adam R; Tibau A; Molto Valiente C; Šeruga B; Ocaña A; Amir E; Templeton AJ
PLoS One; 2022; 17(6):e0268545. PubMed ID: 35687539
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Long-term Survival Benefits in Trials of Immune Checkpoint Inhibitor vs Non-Immune Checkpoint Inhibitor Anticancer Agents Using ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale.
Everest L; Shah M; Chan KKW
JAMA Netw Open; 2019 Jul; 2(7):e196803. PubMed ID: 31290990
[TBL] [Abstract][Full Text] [Related]
8. Temporary authorization for use: does the French patient access programme for unlicensed medicines impact market access after formal licensing?
Degrassat-Théas A; Paubel P; Parent de Curzon O; Le Pen C; Sinègre M
Pharmacoeconomics; 2013 Apr; 31(4):335-43. PubMed ID: 23529210
[TBL] [Abstract][Full Text] [Related]
9. Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries.
Kandolf Sekulovic L; Guo J; Agarwala S; Hauschild A; McArthur G; Cinat G; Wainstein A; Caglevic C; Lorigan P; Gogas H; Alvarez M; Duncombe R; Lebbe C; Peris K; Rutkowski P; Stratigos A; Forsea AM; De La Cruz Merino L; Kukushkina M; Dummer R; Hoeller C; Gorry C; Bastholt L; Herceg D; Neyns B; Vieira R; Arenberger P; Bylaite-Bucinskiene M; Babovic N; Banjin M; Putnik K; Todorovic V; Kirov K; Ocvirk J; Zhukavets A; Ymeri A; Stojkovski I; Garbe C
Eur J Cancer; 2018 Nov; 104():201-209. PubMed ID: 30388700
[TBL] [Abstract][Full Text] [Related]
10. The ESMO-Magnitude of Clinical Benefit Scale for novel oncology drugs: correspondence with three years of reimbursement decisions in Israel.
Hammerman A; Greenberg-Dotan S; Feldhamer I; Birnbaum Y; Cherny NI
Expert Rev Pharmacoecon Outcomes Res; 2018 Feb; 18(1):119-122. PubMed ID: 28617621
[TBL] [Abstract][Full Text] [Related]
11. Appraisal of cancer drugs: a comparison of the French health technology assessment with value frameworks of two oncology societies.
Li J; Vivot A; Alter L; Durand-Zaleski I
Expert Rev Pharmacoecon Outcomes Res; 2020 Aug; 20(4):405-409. PubMed ID: 31240965
[TBL] [Abstract][Full Text] [Related]
12. Access to innovation through the national early access program and clinical trials for patients with malignant melanoma.
Christen C; Belgodère L; Guillot B; Jumeau C; Lorence A; Kerouani-Lafaye G; Brunel L; Turcry F; Monard A; Grudé F; Guyader G; Boudali L; Albin N
Cancer; 2021 Jul; 127(13):2262-2270. PubMed ID: 33764524
[TBL] [Abstract][Full Text] [Related]
13. Value assessment of NMPA-approved new cancer drugs for solid cancer in China, 2016-2020.
Luo J; Ou S; Wei H; Qin X; Peng R; Wang S; Jiang Q
Front Public Health; 2023; 11():1109668. PubMed ID: 36908440
[TBL] [Abstract][Full Text] [Related]
14. Time to access to novel anticancer drugs and the correlation with ESMO-Magnitude of Clinical Benefit Scale in Slovenia.
Janzic U; Knez L; Janzic A; Cufer T
Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):717-723. PubMed ID: 31826655
[No Abstract] [Full Text] [Related]
15. Clinical benefit of systemic treatment in patients with advanced pancreatic and gastrointestinal neuroendocrine tumours according to ESMO-MCBS and ASCO framework.
de Hosson LD; van Veenendaal LM; Schuller Y; Zandee WT; de Herder WW; Tesselaar MET; Klümpen HJ; Walenkamp AME
Ann Oncol; 2017 Dec; 28(12):3022-3027. PubMed ID: 29045525
[TBL] [Abstract][Full Text] [Related]
16. Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit Score.
Cherny NI; de Vries EGE; Dafni U; Garrett-Mayer E; McKernin SE; Piccart M; Latino NJ; Douillard JY; Schnipper LE; Somerfield MR; Bogaerts J; Karlis D; Zygoura P; Vervita K; Pentheroudakis G; Tabernero J; Zielinski C; Wollins DS; Schilsky RL
J Clin Oncol; 2019 Feb; 37(4):336-349. PubMed ID: 30707056
[TBL] [Abstract][Full Text] [Related]
17. [Evaluation of Anti-cancer Therapies with Reimbursement Limited to Comprehensive Cancer Centres Using the European Society for Medical Oncology Magnitude of Clinical Benefit Scale].
Büchler T; Melichar B; Vrána D; Lemstrová R; Fínek J; Dušek L; Petráková K; Prausová J
Klin Onkol; 2017; 30(5):349-360. PubMed ID: 29031037
[TBL] [Abstract][Full Text] [Related]
18. Association between control group therapy and magnitude of clinical benefit of cancer drugs.
Molto C; Tibau A; Bujosa A; Tapia JC; Mittal A; Tamimi F; Amir E
Sci Rep; 2022 Dec; 12(1):21342. PubMed ID: 36494465
[TBL] [Abstract][Full Text] [Related]
19. Five years of EMA-approved systemic cancer therapies for solid tumours-a comparison of two thresholds for meaningful clinical benefit.
Grössmann N; Del Paggio JC; Wolf S; Sullivan R; Booth CM; Rosian K; Emprechtinger R; Wild C
Eur J Cancer; 2017 Sep; 82():66-71. PubMed ID: 28648700
[TBL] [Abstract][Full Text] [Related]
20. Access to innovation through clinical trials and the national early access program for patients with lung cancer in France: focus on atezolizumab and durvalumab.
Jacquet E; Pham F; Taouk B; Kerouani-Lafaye G; Monard A; Brunel L; Albin N
Cancer Chemother Pharmacol; 2023 Sep; 92(3):223-228. PubMed ID: 37439816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
